Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CRBN | Q96SW2 | 15/20 | 0.58 |
| ▸ | IKZF3 | Q9UKT9 | 13/20 | 0.58 |
| ▸ | TNF | P01375 | 7/20 | 0.53 |
| ▸ | IL1B | P01584 | 4/20 | 0.53 |
| ▸ | IKZF1 | Q13422 | 2/20 | 0.53 |
| ▸ | DDB1 | Q16531 | 2/20 | 0.53 |
| ▸ | BRD4 | O60885 | 1/20 | 0.53 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1107991 | 1.00 | CRBN (0.58) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL13948884 | 0.91 | CRBN (0.47) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL19975934 | 0.86 | CRBN (0.53) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL19975931 | 0.84 | CRBN (0.56) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL1107980 | 0.84 | CRBN (0.56) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL21303948 | 0.84 | CRBN (0.66) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL21303950 | 0.84 | CRBN (0.66) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL19503643 | 0.84 | CRBN (0.66) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL1096055 | 0.84 | DDB1 (0.61) | CRBNIKZF3TNFIL1BIKZF1 | |
| SCHEMBL1107974 | 0.84 | DDB1 (0.61) | CRBNIKZF3TNFIL1BIKZF1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200113896-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | SIGNAL PHARM LLC (US) | 2020-04-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200113896-A1 | METHODS FOR TREATING CANCER USING TOR KINASE INHIBITOR COMBINATION THERAPY | MTOR, ULK1, RICTOR | CRBN 869/4885IKZF3 355/4885TNF 798/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.